Crispr Therapeutics AG (NASDAQ:CRSP) saw a significant decrease in short interest during the month of December. As of December 13th, there was short interest totalling 3,400,000 shares, a decrease of 6.1% from the November 28th total of 3,620,000 shares. Based on an average daily volume of 1,000,000 shares, the short-interest ratio is currently 3.4 days. Approximately 9.9% of the company’s stock are sold short.
In related news, President Rodger Novak sold 33,618 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock worth $3,620,760 over the last quarter. 21.40% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. NEXT Financial Group Inc lifted its holdings in Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the last quarter. Coastal Investment Advisors Inc. bought a new position in shares of Crispr Therapeutics during the third quarter worth about $26,000. Farmers & Merchants Trust Co of Chambersburg PA acquired a new position in Crispr Therapeutics during the 4th quarter valued at about $26,000. US Bancorp DE raised its holdings in shares of Crispr Therapeutics by 553.7% during the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after buying an additional 526 shares during the last quarter. Finally, BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics during the second quarter valued at about $39,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.
Several brokerages have commented on CRSP. Goldman Sachs Group boosted their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. ValuEngine lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 price target on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Roth Capital increased their target price on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Finally, Chardan Capital reiterated a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $71.38.
NASDAQ:CRSP opened at $59.90 on Monday. The firm’s fifty day simple moving average is $65.94 and its 200 day simple moving average is $51.65. The firm has a market capitalization of $3.42 billion, a price-to-earnings ratio of -17.41 and a beta of 3.20. Crispr Therapeutics has a twelve month low of $29.34 and a twelve month high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. On average, analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current year.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What is the Shanghai Stock Exchange Composite Index?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.